间歇性抗精神病药物治疗与迟发性运动障碍风险：库拉索锥体外系综合征研究III
Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curaçao Extrapyramidal Syndromes Study III.
作者信息
van Harten P N, Hoek H W, Matroos G E, Koeter M, Kahn R S
机构信息
Dr. David Ricardo Capriles Clinic, Curaçao, Netherlands Antilles.
出版信息
Am J Psychiatry. 1998 Apr;155(4):565-7. doi: 10.1176/ajp.155.4.565.
OBJECTIVE
The authors examined the association between three lifetime medication variables (cumulative amount of neuroleptics, number of interruptions in neuroleptic treatment, cumulative amount of anticholinergics) and the occurrence and severity of tardive dyskinesia.
METHOD
The study was conducted in the only psychiatric hospital of a well-defined catchment area (the Netherlands Antilles). For all patients who had a history of taking neuroleptics for at least 3 months and were currently using neuroleptics (N = 133, mean age = 51.5 years), the presence and severity of tardive dyskinesia were measured with the Abnormal Involuntary Movement Scale.
RESULTS
Of the three lifetime medication variables, only the number of neuroleptic interruptions was significantly related to tardive dyskinesia. The risk of tardive dyskinesia was three times as great for patients with more than two neuroleptic interruptions as for patients with two or fewer interruptions.
CONCLUSIONS
This finding supports the schizophrenia protocol of long-term neuroleptic treatment rather than targeted or intermittent neuroleptic treatment.
目的
作者研究了三种终生用药变量（抗精神病药物累积量、抗精神病药物治疗中断次数、抗胆碱能药物累积量）与迟发性运动障碍的发生及严重程度之间的关联。
方法
该研究在一个明确界定的集水区（荷属安的列斯群岛）的唯一一家精神病医院进行。对于所有有服用抗精神病药物至少3个月病史且目前正在使用抗精神病药物的患者（N = 133，平均年龄 = 51.5岁），使用异常不自主运动量表测量迟发性运动障碍的存在情况及严重程度。
结果
在三种终生用药变量中，只有抗精神病药物治疗中断次数与迟发性运动障碍显著相关。抗精神病药物治疗中断次数超过两次的患者发生迟发性运动障碍的风险是中断次数为两次或更少的患者的三倍。
结论
这一发现支持精神分裂症的长期抗精神病药物治疗方案，而非针对性或间歇性抗精神病药物治疗。
Zotero 插件